Second, recent PI3K inhibitors (e.g., alpelisib or buparlisib; with better pharmacokinetics and reduced toxicity than wortmannin) are often investigated in melanoma in combination with BRAF inhibitors (e.g., vemurafenib) or MEK inhibitors (e.g., trametinib) to overcome resistance and improve treatment efficacy [34]. Here, MAP2K7 is linked to melanoma.